A Phase II Study of AS1411 in Renal Cell Carcinoma

PHASE2UnknownINTERVENTIONAL
Enrollment

30

Participants

Timeline

Start Date

August 31, 2008

Primary Completion Date

September 30, 2009

Study Completion Date

March 31, 2010

Conditions
Metastatic Renal Cell Carcinoma
Interventions
DRUG

AS1411

AS1411 40 mg/kg/day) will be administered on days 1-4 via a continuous iv infusion every 28-day cycle for up to 2 cycles

Trial Locations (7)

29403

Medical University of South Carolina, Charleston

40202

James Graham Brown Cancer Center, University of Louisville, Louisville

46107

St Francis Hospital, Beech Grove

91010

City of Hope, Duarte

94143

University of California San Francisco, San Francisco

95817

University of California, Davis Cancer Center, Sacramento

02115

Lank Center for Genitourinary Oncology, Dana-Farber Cancer Institute, Boston

Sponsors

Lead Sponsor

All Listed Sponsors
lead

Antisoma Research

INDUSTRY

NCT00740441 - A Phase II Study of AS1411 in Renal Cell Carcinoma | Biotech Hunter | Biotech Hunter